Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an "omics" approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Little evidence is available on circulating phosphatidylinositol and phosphatidylserine, which have been found to be higher in MASL(101, 102) or only in MASH (phosphatidylinositol).108”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“High levels of plasma ceramides are correlated with the severity of MASLD and reflect hepatic ceramide accumulation.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Plasma saturated/unsaturated fatty acid TAGs have been found to be elevated,102,103 and associated with IR11,104 in individuals with MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Patients with MASH have 20% higher ceramide concentrations compared to healthy individuals.100,102,104,117”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“A few studies have also investigated circulating lipidomic species in patients with advanced forms of MASH (F3), fibrosis, and cirrhosis, showing an increase in circulating levels of some ceramides (d18:1/20:0, d18:1/22:0, d18:1/23:0, d18:1/24:1, d18:1/24:0) and a decrease in hexosylceramide,115 some glucosylceramide (d18:1/24:1, d18:1/26:1, 18:1/26:0), SM, PC, LPC, and phosphatidylinositol94,102”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Lipidomics reveals a remarkable diversity of lipids in human plasma
Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009449 · Cited by 1,341
Self-citation
Cited by
Items 101–200 of 374
Wruck, W., Graffmann, N., Kawala, M.-A., & Adjaye, J. (2016) · Stem Cells · doi:10.1002/stem.2454 · Cited by 52
Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide
Nikolova‐Karakashian, M. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.11.004 · Cited by 55
Patterson, R. E., Kirpich, A., Koelmel, J. P., Kalavalapalli, S., Morse, A. M., Cusi, K. J., Sunny, N. E., McIntyre, L. M., Garrett, T. J., & Yost, R. A. (2017) · Metabolomics · doi:10.1007/s11306-017-1280-1 · Cited by 49
“targeted a wide range of lipid classes in NAFLD plasma and liver by using the best extraction and analysis techniques for each lipid class (Gorden et al. 2015).”
MethodHepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models
Chiappini, F., Desterke, C., Bertrand-Michel, J., Guettier, C., & Le Naour, F. (2016) · Scientific Reports · doi:10.1038/srep31587 · Cited by 48
Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis
Raselli, T., Hearn, T., Wyss, A., Atrott, K., Peter, A., Frey-Wagner, I., Spalinger, M. R., Maggio, E. M., Sailer, A. W., Schmitt, J., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m093229 · Cited by 48
“NASH from steatosis in a previous lipidomics study (48).”
BackgroundResultAhmed, E., El-Derany, M. O., Anwar, A. M., Saied, E. M., & Magdeldin, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010210 · Cited by 50
“Previously, phospholipids were depleted in patients with NASH [54].”
BackgroundLiberating Chiral Lipid Mediators, Inflammatory Enzymes, and LIPID MAPS from Biological Grease
Dennis, E. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.x116.723791 · Cited by 48
“The creation of the LIPID MAPS initiative in 2003 and the ensuing development of the lipidomics field have revealed that lipid metabolites are central to human metabolism.”
BackgroundInfluentialSelf-citationLiu, H., Chen, T., Xie, X., Wang, X., Luo, Y., Xu, N., Sa, Z., Zhang, M., Chen, Z., Hu, X., et al. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c03379 · Cited by 46
Gengatharan, J. M., Handzlik, M. K., Chih, Z. Y., Ruchhoeft, M. L., Secrest, P., Ashley, E. L., Green, C. R., Wallace, M., Gordts, P. L. S. M., & Metallo, C. M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.016 · Cited by 53
Sphingolipids in food and their critical roles in human health
Wang, X., Wang, Y., Xu, J., & Xue, C. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1736510 · Cited by 46
Kayser, B. D., Lhomme, M., Dao, M. C., Ichou, F., Bouillot, J., Prifti, E., Kontush, A., Chevallier, J., Aron‐Wisnewsky, J., Dugail, I., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.63 · Cited by 49
Jurowski, K., Kochan, K., Walczak‐Skierska, J., Barańśka, M., Piekoszewski, W., & Buszewski, B. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.10.014 · Cited by 51
Ruiz, M., Cuillerier, A., Daneault, C., Deschênes, S., Frayne, I. R., Bouchard, B., Forest, A., Legault, J. T., Vaz, F. M., Rioux, J. D., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123231 · Cited by 52
Bioactive signalling lipids as drivers of chronic liver diseases
Kaffe, E., Tisi, A., Magkrioti, C., Aidinis, V., Mehal, W. Z., Flavell, R. A., & Maccarrone, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.029 · Cited by 47
Othman, A., Benghozi, R., Alecu, I., Yu, W., Niesor, E. J., von Eckardstein, A., & Hornemann, T. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.011 · Cited by 43
Taylor, H. E., Simmons, G. E., Jr., Mathews, T. P., Khatua, A. K., Popik, W., Lindsley, C. W., D’Aquila, R. T., & Brown, H. A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004864 · Cited by 43
“Cellular analysis of dNTPs was performed as previously reported [47,48].”
MethodSelf-citationThe interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Neutral sphingomyelinase‐2 and cardiometabolic diseases
Sindhu, S. T. A. K., Leung, Y. H., Arefanian, H., Madiraju, S. R. M., Al‐Mulla, F., Ahmad, R., & Prentki, M. (2021) · Obesity Reviews · doi:10.1111/obr.13248 · Cited by 48
Challenges in mass spectrometry-based lipidomics of neutral lipids
Murphy, R. C. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.07.023 · Cited by 43
Self-citationBiomarker discovery for chronic liver diseases by multi-omics – a preclinical case study
Veyel, D., Wenger, K., Broermann, A., Bretschneider, T., Luippold, A. H., Krawczyk, B., Rist, W., & Simon, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-58030-6 · Cited by 41
Concise review of lipidomics in nonalcoholic fatty liver disease
Béland‐Bonenfant, S., Rouland, A., Petit, J., & Vergès, B. L. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101432 · Cited by 38
Non-alcoholic fatty liver disease: Insights from sphingolipidomics
Montefusco, D. J., Allegood, J. C., Spiegel, S., & Cowart, L. A. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.078 · Cited by 40
“In Gorden et al [23], a random group of patient biopsies were scored histologically and categorized as normal liver, livers showing steatosis, livers with nonalcoholic steatohepatitis (NASH), or cirrhotic liver, creating the opportunity to compare and contrast lipidomics trends among these patient groups.”
BackgroundInsights into genetic variants associated with NASH-fibrosis from metabolite profiling
Mann, J. P., Pietzner, M., Wittemans, L. B., Rolfe, E. D. L., Kerrison, N. D., Imamura, F., Forouhi, N. G., Fauman, E., Allison, M. E., Griffin, J. L., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa162 · Cited by 38
“Higher sphingomyelins have been implicated in the development of cirrhosis (30,31) as well as insulin resistance (32,33).”
BackgroundDraijer, L. G., Froon-Torenstra, D., van Weeghel, M., Vaz, F. M., Bohte, A. E., Holleboom, A. G., Benninga, M. A., & Koot, B. G. P. (2020) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002875 · Cited by 43
“Similar changes in this cluster of lipids were found by Gorden et al (32) when comparing adults with histologically normal livers to those with all stages of NAFLD.”
InfluentialBarz, M. L., Vors, C., Combe, E., Joumard‐Cubizolles, L., Lecomte, M., Joffre, F., Trauchessec, M., Pesenti, S., Loizon, E., Breyton, A.-E., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146161 · Cited by 38
“Trends Endocrinol Metab 2017;28(7):506–518.”
Comprehensive Analysis of NAFLD and the Therapeutic Target Identified
Wen, W., Wu, P., Zhang, Y., Chen, Z., Sun, J. M., & Chen, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.704704 · Cited by 41
Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection
Bowman, E., & Funderburg, N. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00442-9 · Cited by 44
Yu, T., Zhou, Z., Liu, S., Li, C., Zhang, Z., Zhang, Y., Jin, W., Liu, K., Mao, S., Zhu, L., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.006 · Cited by 40
Self-citationSeubnooch, P., Montani, M., Dufour, J., & Masoodi, M. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100599 · Cited by 45
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients
Cheung, A. C., Figueredo, C. J., & Rinella, M. E. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000058 · Cited by 41
The RNA binding protein human antigen R is a gatekeeper of liver homeostasis
Subramanian, P., Gargani, S., Palladini, A., Chatzimike, M., Grzybek, M., Peitzsch, M., Papanastasiou, A. D., Pyrina, I., Ntafis, V., Gercken, B., et al. (2021) · Hepatology · doi:10.1002/hep.32153 · Cited by 35
“[27,28] During human NAFLD, TAG_50:1 is enriched [28– 31] ; similarly, we found that this TAG was increased in HuR-deficient livers at steady state (Figure 5E).”
BackgroundIanni, F., Saluti, G., Galarini, R., Fiorito, S., Sardella, R., & Natalini, B. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.04.038 · Cited by 33
Castañé, H., Baiges‐Gayà, G., Hernández‐Aguilera, A., Rodríguez‐Tomàs, E., Fernández‐Arroyo, S., Herrero, P., Delpino-Rius, A., Canela-Canela, N., Menéndez, J. A., Camps, J., et al. (2021) · Biomolecules · doi:10.3390/biom11030473 · Cited by 36
“Results among studies are also difficult to compare, because there is a significant overlap between plasma and liver lipidomes [99,100], the crucial role of mitochondrial dysfunction in NAFLD pathogenesis is difficult to assess [101,102] and the presence of covariates in NAFLD are not always adjusted [103].”
BackgroundMetabolomics at the cutting edge of risk prediction of MASLD
Tan, E. Y., Muthiah, M. D., & Sanyal, A. J. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101853 · Cited by 50
Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH
Yu, X., Huang, C., Evers, M. J. W., Liu, J., Ting, H. J., Zhang, S., Chong, S. Y., Tan, M. S., Wang, S., Sayed, N., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx2681 · Cited by 37
Deciphering the role of aberrant DNA methylation in NAFLD and NASH
Vachher, M., Bansal, S., Kumar, B., Yadav, S., & Burman, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11119 · Cited by 34
“Variants of PNPLA3 have been shown to correspond with NAFLD prevalence across ethnicities [47].”
BackgroundMolecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma
Rajesh, Y., & Sarkar, D. (2020) · Cancers · doi:10.3390/cancers12051290 · Cited by 34
Lipidomics analysis reveals new insights into the goose fatty liver formation
Wei, R., Ning, R., Han, C., Wei, S., Teng, Y., Li, L., Liu, H., Hu, S., Kang, B., & Xu, H. (2022) · Poultry Science · doi:10.1016/j.psj.2022.102428 · Cited by 52
Bourganou, M. V., Chondrogianni, M. E., Kyrou, I., Flessa, C., Chatzigeorgiou, A., Oikonomou, E. K., Lambadiari, V., Randeva, H. S., & Kassi, E. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041589 · Cited by 37
“In NAFLD, a significant disruption in the hepatic elongation of long-chain fatty acids is evident, resulting in an elevated omega-6 to omega-3 ratio and heightened flow in the omega-6 pathway [206,207,212].”
Gai, Z., Gui, T., Alecu, I., Lone, M. A., Hornemann, T., Chen, Q., Visentin, M., Hiller, C., Häusler, S., & Kullak-Ublick, G. A. (2019) · Liver International · doi:10.1111/liv.14340 · Cited by 31
Genetic regulation of liver lipids in a mouse model of insulin resistance and hepatic steatosis
Norheim, F., Krishnan, K. C., Bjellaas, T., Vergnes, L., Pan, C., Parks, B. W., Meng, Y., Lang, J., Ward, J. A., Reue, K., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209684 · Cited by 32
“These analyses have highlighted the complexity of lipid species and generated correlative links to several chronic diseases (Gorden et al, 2015; Luukkonen et al, 2016; Peng et al, 2018).”
BackgroundLiu, Z., Wang, Y., Borlak, J. T., & Tong, W. (2016) · Scientific Reports · doi:10.1038/srep23709 · Cited by 30
ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study
Cyr, B. S., Keane, R. W., & Vaccari, J. P. D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228580 · Cited by 32
“An in-depth analysis of plasma lipids proposed a signature of 20 candidates to distinguish NASH from steatosis [40].”
BackgroundBuratta, S., Shimanaka, Y., Costanzi, E., Ni, S., Urbanelli, L., Kono, N., Morena, F., Sagini, K., Giovagnoli, S., Romani, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84268-9 · Cited by 33
Protective effects of fish oil on pre-diabetes: a lipidomic analysis of liver ceramides in rats
Taltavull, N., Ras, R., Mariné, S., Romeu, M., Giralt, M., Méndez, L., Medina, I., Ramos‐Romero, S., Torres, J. L., & Nogués, M. R. (2016) · Food & Function · doi:10.1039/c6fo00589f · Cited by 37
Sa, R., Zhang, W., Ge, J., Wei, X., Zhou, Y., Landzberg, D. R., Wang, Z., Han, X., Chen, L., & Yin, H. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw016 · Cited by 29
“However, limited success has been achieved thus far in this field due to the complex and heterogeneous nature of NAFLD (Wree et al., 2013; Gorden et al., 2015).”
BackgroundYang, R., Hu, C., Sun, W., Pan, Q., Shen, F., YANG, Z. K., Su, Q., Xu, G., & Fan, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-11278-x · Cited by 36
Mucinski, J. M., Manrique‐Acevedo, C., Kasumov, T., Garrett, T. J., Gaballah, A., & Parks, E. J. (2020) · Lipids · doi:10.1002/lipd.12244 · Cited by 27
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Wang, J., Jiang, S., Hu, A., Zhou, A.-W., Hu, T., Li, H., Fan, Y., & Lin, K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27325 · Cited by 39
“A study presented 20 comparable plasma metabolite panels that could unmistakably distinguish NASH from fatty change, and lipid and water metabolites may be considered indicators for disease progression in NAFLD [75].”
BackgroundMouskeftara, T., Deda, O., Papadopoulos, G., Chatzigeorgiou, A., & Gika, H. (2024) · Molecules · doi:10.3390/molecules29071494 · Cited by 28
Ramos‐Molina, B., Rossell, J., de, A. P.-M., Pardina, E., Genua, I., Rojo-López, M. I., Julián, M. T., Alonso, N., Julve, J., & Mauricio, D. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1400961 · Cited by 32
“…addition, several long-chain ceramides, dihydroceramides, or 1-deoxy-dihydroceramides have also been reported to display an overlap between differentially-expressed lipids in both the liver and peripheral circulation, thereby unveiling their potential as biomarkers for diagnostic purposes (67, 71).”
BackgroundMacrophages in the pathophysiology of NAFLD: The role of sex differences
Ministrini, S., Montecucco, F., Sahebkar, A., & Carbone, F. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13236 · Cited by 29
In vitro effects of Triclocarban on adipogenesis in murine preadipocyte and human hepatocyte
Dong, M., Yuan, P., Song, Y., Lei, H., Chen, G., Zhu, X., Wu, F., Chen, C., Liu, C., Shi, Z., et al. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.122829 · Cited by 27
Alterations in lipid profile upon uterine fibroids and its recurrence
Tonoyan, N. M., Chagovets, V., Starodubtseva, N. L., Tokareva, A., Chingin, K., Kozachenko, I. F., Adamyan, L. V., & Евгеньевич, Ф. В. (2021) · Scientific Reports · doi:10.1038/s41598-021-89859-0 · Cited by 33
The lipidome in nonalcoholic fatty liver disease: actionable targets
Pirola, C. J., & Sookoian, S. C. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100073 · Cited by 30
“Combined explorations in plasma and liver tissue Gorden (21) Profiling of lipids from plasma, liver biopsies,and urine samples in adult patients classified on the basis of liver histology as normal, steatotic, NASH, or cirrhotic NAFL (n = 17) and NASH (n = 20); Cirrhosis (n = 20), controls (n = 31).”
BackgroundKania‐Korwel, I., Wu, X., Wang, K., & Lehmler, H. (2017) · Toxicology · doi:10.1016/j.tox.2017.09.005 · Cited by 29
Vouilloz, A., Bourgeois, T., Diedisheim, M., Pilot, T., Jalil, A., Guern, N. L., Bergas, V., Rohmer, N., Castelli, F. A., Leleu, D., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156051 · Cited by 31
Wang, Z., Zheng, K. I., Wang, X., Qiao, J., Li, Y., Zhang, L. R., Zheng, M., & Wu, J. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.05.008 · Cited by 27
Wang, H., Chen, Z., Wang, M., Long, M., Ren, T., Chen, C., Dai, X., Yang, S., & Tan, S. (2022) · Foods · doi:10.3390/foods11121747 · Cited by 31
“Preventing the accumulation of ceramides can prevent insulin resistance, cardiovascular diseases, and hepatic steatosis [31,32].”
BackgroundFlóres, Y. N., Amoon, A. T., Su, B., Velázquez‐Cruz, R., Ramírez‐Palacios, P., Salmerón, J., Rivera‐Paredez, B., Sinsheimer, J. S., Lusis, A. J., Huertas‐Vázquez, A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01526-5 · Cited by 32
“The very long chain dihydroceramides and polyunsaturated PEs can discriminate NAFLD from NASH subjects [43].”
BackgroundWu, Y., Chen, Z., Fuda, H., Tsukui, T., Wu, X., Shen, N., Saito, N., Chiba, H., & Hui, S. (2021) · Antioxidants · doi:10.3390/antiox10101602 · Cited by 28
Nanodrug Delivery Systems for Metabolic Chronic Liver Diseases: Advances and Perspectives
Athanasopoulou, F., Manolakakis, M., Vernia, S., & Kamaly, N. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0261 · Cited by 30
Zhou, Y., Dai, Z., Deng, K., Wang, Y., Ying, J., Chu, D., Zhou, J., & Tang, C. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.05.012 · Cited by 27
“Several studies have revealed elevated TG levels in patients with NAFLD [31,32].”
BackgroundRaffaele, M., Carota, G., Sferrazzo, G., Licari, M., Barbagallo, I. A., Sorrenti, V., Signorelli, S. S., & Vanella, L. (2019) · Antioxidants · doi:10.3390/antiox8080277 · Cited by 27
“Lipid droplets accumulation was examined by using an inverted multichannel LED fluorescence microscope (Evos, Life Technologies, Grand Island, NY, USA).”
MethodEffects of constant light exposure on sphingolipidomics and progression of NASH in high‐fat‐fed rats
Yue, F., Xia, K., Lin, W., Lin, X., Wu, S., Shi, Y. Q., Lam, S. M., Shui, G., Xiang, X., Russell, R., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15005 · Cited by 27
Analytical challenges in human plasma lipidomics: A winding path towards the truth
Vvedenskaya, O., Wang, Y., Ackerman, J. M., Knittelfelder, O. L., & Shevchenko, A. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.10.013 · Cited by 23
Camacho‐Muñoz, D., Kiezel‐Tsugunova, M., Kiss, O., Uddin, M., Sundén, M., Ryaboshapkina, M., Lind, L., Oscarsson, J., & Nicolaou, A. (2021) · The FASEB Journal · doi:10.1096/fj.202100380rrr · Cited by 23
Guo, Z., Zhang, T., Yun, Z., Jin, Q., Cao, X., Kong, D., Yao, Y., Li, X., Zhang, J., & Ye, Y. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1108086 · Cited by 24
Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese
Puri, P., Xu, J., Vihervaara, T., Katainen, R., Ekroos, K., Daita, K., Min, H., Joyce, A., Mirshahi, F., Tsukamoto, H., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066175 · Cited by 24
Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future
Adams, L. A., & Chan, W. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1713006 · Cited by 26
Role of dietary and nutritional interventions in ceramide-associated diseases
Wang, S., Jin, Z., Wu, B., Morris, A. J., & Deng, P. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100726 · Cited by 27
Cong, S., Li, Z., Yu, L., Liu, Y., Hu, Y., Bi, Y., & Cheng, M. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00553-4 · Cited by 22
Wang, G., Zhang, X., Wang, C., & Guan, Y. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.75 · Cited by 22
Truman, J., Ruiz, C. F., Montal, E. D., García-Barros, M., Mileva, I., Snider, A. J., Hannun, Y. A., Obeid, L. M., & Mao, C. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100154 · Cited by 19
“syndrome (23), nonalcoholic steatohepatitis (24), and”
Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α
Xia, J., Chen, H., Wang, X., Chen, W., Lin, J., Xu, F., Nie, Q., Ye, C., Zhong, B., Zhao, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48954-2 · Cited by 22
“TheNAS,alsoknownastheNAFLDactivityscore(NAS),iscalculatedas the sum of three histological components, that is, steatosis (0 – 3), ballooning (0 – 2)andlobularin fl ammation (0 – 3).”
BackgroundInfluentialEngineered Hydrogels for Organoid Models of Human Nonalcoholic Fatty Liver Disease
Liu, Y., Gilchrist, A. E., Johansson, P. K., Guan, Y., Deras, J. D., Liu, Y., Ceva, S., Huang, M. S., Navarro, R. S., Enejder, A. M. K., et al. (2025) · Advanced Science · doi:10.1002/advs.202417332 · Cited by 29
Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity
Shih, L.-M., Tang, H.-Y., Lynn, K., Huang, C.-Y., Ho, H., & Cheng, M. (2018) · Molecules · doi:10.3390/molecules23112862 · Cited by 23
Olson, E., Suh, J. H., Schwarz, J., Noworolski, S. M., Jones, G. M., Barber, J. R., Erkin‐Cakmak, A., Mulligan, K. M., Lustig, R. H., & Mietus‐Snyder, M. (2022) · Nutrients · doi:10.3390/nu14071432 · Cited by 26
“In a double-blinded lipidomics screen of plasma from adult patients with normal, steatotic, or fibrotic liver disease, deoxy-dhCers were among the plasma metabolites that distinguished the progression from NAFLD to NASH [44].”
BackgroundLu, H., George, J., Eslam, M., Villanueva, A., Bolondi, L., Reeves, H. L., McCain, M. V., Chambers, E. S., Ward, C. E., Sartika, D., et al. (2022) · Liver Cancer · doi:10.1159/000525911 · Cited by 22
Konstantynowicz-Nowicka, K., Berk, K., Chabowski, A., Kasacka, I., Bielawiec, P., Łukaszuk, B., & Harasim‐Symbor, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153829 · Cited by 20
“In line with these results are studies conducted on rats with diet-induced NAFLD as well as human liver biopsies from patients diagnosed with this disease, whereas in hepatocytes an increased lipid accumulation was also observed [16,17].”
ResultAdvances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
Sessa, A. D., Riccio, S., Pirozzi, E., Verde, M., Passaro, A. P., Umano, G. R., Guarino, S., del Giudice, E. M., & Marzuillo, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i25.3815 · Cited by 20
Vural, H., Armutçu, F., Akyol, Ö., & Weiskirchen, R. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.018 · Cited by 23
Yu, T., Wu, L., Zhang, T., Hao, H., Dong, J., Xu, Y., Yang, H., Liu, H., Xie, L. Y., Wang, G., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154870 · Cited by 24
Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach
Mouskeftara, T., Kalopitas, G., Liapikos, T., Arvanitakis, K., Germanidis, G. S., & Gika, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115965 · Cited by 20
“In a relative publication, LPE levels were found to be higher in a steatosis group compared to in normal liver tissue, but not in NASH, suggesting increased lipid turnover rather than hydrolysis [11].”
BackgroundInfluentialEndoplasmic reticulum stress at the forefront of fatty liver diseases and cancer
Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 27
“141 Interestingly, DAG, a lipid intermediate suggested to have a prognostic value in type 2 diabetes (T2D), is significantly less abundant in the livers of fibrosis-affiliated MASH compared with those with MAFL.”
Xu, C., Song, D., Holck, A. L., Zhou, Y., & Liu, R. (2020) · ACS Omega · doi:10.1021/acsomega.9b04402 · Cited by 18
Li, Q., Qian, J., Li, Y., Huang, P., Liang, H., Sun, H., Liu, C., Peng, J., Lin, X., Chen, X., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.07.004 · Cited by 19
Self-citationTaha, M. M., Abdelghany, A. I., & Draz, R. S. (2021) · Journal of Acupuncture and Meridian Studies · doi:10.51507/j.jams.2021.14.1.21 · Cited by 21
“Gorden et al. [5] explained that concise “signatures” of lipids could be a useful indication of reaction to treatment in the management of NAFLD and may serve as biomarkers for its progression.”
Li, M., Larsen, F. T., van den Heuvel, M. C., Gier, K., Gorter, A. R., Oosterhuis, D., Bijzet, J., de Meijer, V. E., Ravnskjær, K., Nagelkerke, A., et al. (2024) · Nutrients · doi:10.3390/nu16050626 · Cited by 21
“Similar trends were also observed in other studies where CYP2E1 , CYP2C19 , and CYP2C8 showed down-regulation that followed the disease stage progression [25].”
BackgroundResultInfluentialMuralidharan, S., Lee, J. W. J., Lim, Y. S., Muthiah, M. D., Tan, E., Demicioglu, D., Shabbir, A., Loo, W. M., Koo, C. S., Lee, Y. M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156063 · Cited by 22
Chamulitrat, W., Jansakun, C., Li, H., & Liebisch, G. (2020) · Biomolecules · doi:10.3390/biom10091332 · Cited by 17
Dysregulation of the secretory pathway connects Alzheimer’s disease genetics to aggregate formation
Kuo, C., Chiang, A. W. T., Baghdassarian, H., & Lewis, N. E. (2021) · Cell Systems · doi:10.1016/j.cels.2021.06.001 · Cited by 21
Frandsen, H. S., Vej-Nielsen, J. M., Smith, L. E., Sun, L., Mikkelsen, K. L., Thulesen, A. P., Hagensen, C. E., Yang, F., & Rogowska-Wrzesińska, A. (2022) · Cells · doi:10.3390/cells11203216 · Cited by 18
Cui, X., Yao, M., Feng, Y., Li, C., Li, Y., Guo, D., & He, S. (2023) · The FASEB Journal · doi:10.1096/fj.202201705rr · Cited by 20
Self-citationFurukawa, T., Fuda, H., Miyanaga, S., Watanabe, C., Chiba, H., & Hui, S. (2016) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2016.09.003 · Cited by 17
He, D., Su, Y., Meng, D., Wang, X., Wang, J., & Ye, H. (2021) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2021.10.001 · Cited by 17
Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics
Flam, E. L., Haas, J. T., & Staels, B. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119054 · Cited by 19
COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD
Chen, H., & Chen, Q. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72461 · Cited by 21
“HIF-1α has been reported to have the potential to promote MAFLD development [142].”
BackgroundComparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross‐Sectional Study
Mann, J. P., Jenkins, B., Furse, S., Snowden, S. G., Alisi, A., Draijer, L. G., Karnebeek, K., Kelly, D. A., Koot, B. G. P., Mosca, A., et al. (2022) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003418 · Cited by 15
“In addition, liver biopsy samples were not available for lipidomics, which would have improved our understanding of lipid metabolism at the level of the hepatocyte; however, studies that have included paired liver and plasma samples have found considerable overlap (12).”
Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
Huang, J., Sigon, G., Mullish, B. H., Wang, D., Sharma, R., Manousou, P., & Forlano, R. (2023) · Nutrients · doi:10.3390/nu15081992 · Cited by 16
Metadata
- Authors
- Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., Duan, J., Sullards, M. C., Leiker, T. J., Barkley, R. M., Quehenberger, O., Armando, A. M., Milne, S. B., Mathews, T. P., Armstrong, M. D., Li, C., Melvin, W. V., Clements, R. H., Washington, M. K., Mendonsa, A. M., Witztum, J. L., Guan, Z., Glass, C. K., Murphy, R. C., Dennis, E. A., Merrill, A. H., Russell, D. W., Subramaniam, S., & Brown, H. A.
- Affiliations
- Vanderbilt University Medical Center (US)
- University of California San Diego (US)
- The University of Texas Southwestern Medical Center (US)
- Georgia Institute of Technology (US)
- University of Colorado Denver (US)
- Duke Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Subramaniam, Shankar
- Brown, H.Alex
- ORCID
- Fahy, Eoin
- Maurya, Mano R.
- Gupta, Shakti
- Spann, Nathanael J.
- McDonald, Jeffrey G.
- Duan, Jingjing
- Barkley, Robert M.
- Quehenberger, Oswald
- Armando, Aaron M.
- Milne, Stephen B.
- Mathews, Thomas P.
- Washington, M.Kay
- Witztum, Joseph L.
- Guan, Ziqiang
- Glass, Christopher K.
- Murphy, Robert C.
- Dennis, Edward A.
- Merrill, Alfred H.
- Russell, David W.
- Subramaniam, Shankar
- Brown, H.Alex
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 56
- Issue
- 3
- Pages
- 722-736
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4340319
- OpenAlex
- W2134541386
- Cited by
- 372
- References
- 73
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 38 · 2023: 34 · 2022: 34 · 2021: 56 · 2020: 42 · 2019: 32 · 2018: 25 · 2017: 20 · 2016: 21 · 2015: 11
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2040 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL106579)
- National Institute of Mental Health (T32MH093366)
- National Institute of General Medical Sciences (U54GM069338, R24GM107784, GM U54 069338)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK074868, P30DK058404)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, steatosis, disease progression, lipidomics, plasma metabolites, biomarkers, glycerophospholipids, sphingolipids, sterols, liver biopsy, diagnostic signature, NAFLD staging
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Biomarkers, Polymorphism, Single Nucleotide, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.